November 2011

Onconova extends agreement with BioClinica

Wednesday, November 30, 2011

BioClinica has reported that Onconova Therapeutics has extended agreements using BioClinica Express electronic data capture (EDC) and data management services to support their clinical trials world-wide. Onconova has a number of clinical-stage products and a growing number of pre-clinical candidates. These development stage compounds are novel small molecules for the treatment of a broad range of hematologic malignancies and solid tumors.

[Read More]

Omeros unlocks 20% of Class A orphans

Wednesday, November 30, 2011

Omeros has reported that with its identification of compounds that interact
selectively with each of four additional orphan G protein-coupled receptors (GPCRs) – GPR19, GPR20, GPR31 and GPR141 – it has now unlocked over 20% of the 77 Class A orphans. GPCRs represent the premier family of drug targets, with more than 30% of currently marketed drugs targeting only 46 GPCRs. There are approximately 120 orphan GPCRs, and Omeros is initially targeting Class A orphan GPCRs.

[Read More]

Rhythm names chief scientific officer

Wednesday, November 30, 2011

Rhythm has named Lex Van der Ploeg, PhD, chief scientific officer. Van der Ploeg brings to Rhythm more than 25 years of drug development experience in obesity, metabolic diseases, and other therapeutic areas.

[Read More]

Infinity, Mundipharma extend global alliance

Tuesday, November 29, 2011

Infinity Pharmaceuticals has reported that Mundipharma International has committed to providing over $50 million in funding in 2013 for the continued development of IPI-145, Infinity’s potent, oral inhibitor of phosphoinositide-3-kinase (PI3K) delta and gamma, as well as development candidates arising out of Infinity’s innovative discovery programs. An extension of the companies’ global strategic alliance, this funding reflects the broad commercial potential of IPI-145 in both hematologic cancers and inflammatory conditions as well as the continued productivity of Infinity’s discovery and development programs.

[Read More]